September 24, 2025
Image source: Adobe Stock
Alibaba Group Holding Ltd.’s shares surged to their highest in nearly four years after revealing plans to ramp up AI spending past an original $50 billion-plus target, joining tech leaders pledging ever-greater sums toward a global race for technological breakthroughs.
Chief Executive Officer Eddie Wu anticipates overall investment in artificial intelligence accelerating to some $4 trillion worldwide over the next five years - and Alibaba needs to keep up.
The company will soon add to a plan laid out in February to spend more than 380 billion yuan ($53 billion) developing AI models and infrastructure over three years, he said.
His cloud division, which already operates services from the US to Australia, intends to launch its first data centers in Brazil, France and the Netherlands in the coming year. Yahoo Finance reports.
🤖 Micron's Q4 earnings surpass Wall Street's expectations in latest test of AI trade
Micron stock rose early on Wednesday after the chipmaker reported fiscal fourth quarter earnings that surpassed Wall Street's expectations.
The results after the bell on Tuesday are seen as a positive signal for the AI trade and for investors hoping the chipmaker's stock can sustain its recent upswing.
The stock briefly climbed around 2% in premarket trading, having risen soon after the report to $171.50, above its all-time intraday high last week. Yahoo Finance reports.
📊 S&P 500, Nasdaq futures tick up as investors weigh Powell's remarks
Futures for the S&P 500 and the Nasdaq edged higher on Wednesday as investors assessed cautious commentary from U.S. Federal Reserve Chair Jerome Powell and looked ahead to key economic data later in the week.
While the recent numbers point to a resilient economy, comments from Fed officials have injected some wariness, especially about the labor market. Powell added to the measured tone on Tuesday, noting that asset prices appeared fairly highly valued. Reuters reports.
💊 Eli Lilly to build $6.5 billion Texas manufacturing facility for obesity pill, other drugs
Eli Lilly on Tuesday said it will spend $6.5 billion to build a manufacturing facility in Houston, Texas, to boost production of the company’s pipeline of so-called small molecule drugs, including its closely watched experimental obesity pill.
It is the second in a string of new planned U.S. investments by the drugmaker. Eli Lilly announced in February that it would spend at least $27 billion to build four new domestic manufacturing plants, adding to $23 billion in previous investments since 2020.
Eli Lilly said it will announce the two remaining U.S. sites this year. The company expects to begin making medicines at all four facilities within five years. CNBC reports.
📊 Defense stocks rally as Trump, in a major shift, says Ukraine can win back territory from Russia
Global defense stocks moved higher on Wednesday after U.S. President Donald Trump, in a major rhetorical shift, said Ukraine could retake territory currently occupied by Russia.
In a post published overnight on his Truth Social platform, Trump said that Kyiv, with the support of the European Union and the NATO military coalition, “is in a position to fight and WIN all of Ukraine back in its original form.”
The EU and NATO have offered military and humanitarian support to Ukraine - which is not currently a member of either organization - since the start of Russia’s invasion in 2022. CNBC reports.
🏭 Lithium Americas soars on report Trump administration seeking equity stake
U.S.-listed shares of Lithium Americas surged more than 70% in premarket trading on Wednesday after a report said the Trump administration was seeking an equity stake of up to 10% in the miner, the latest sign of involvement in industries the government sees as critical to national security.
Reuters reported late on Tuesday, citing two people familiar with the discussions, that the administration was discussing taking the stake in the company as part of talks to renegotiate a $2.26 billion government loan for its Thacker Pass lithium mine. Yahoo Finance reports.
(All pricing and percent gains are based on Early Pre-Market from 4:00 AM to 7:00 AM Eastern Time)
Benzinga reports.
1) SHFS: SHF Holdings
Total gain: +206.74%
2) AQMS: Aqua Metals
Total gain: +57.77%
3) LAC: Lithium Americas
Total gain: +53.74%
4) CYCN: Cyclerion Therapeutics
Total gain: +41.05%
5) ZONE: CleanCore Solutions
Total gain: +34.84%
The closing price of the top three market percent gainers trading near or above $3 on September 23.
Benzinga reports.
*All pricing and percent gains are based on regular market trading hours from 9:30am to 4:00pm Eastern Time
1) SLE: Super League Enterprise
Total gain: +156.09%
The company announced the execution of definitive agreements for a private placement financing with accredited investors, anchored by a $10 million strategic equity investment from Evo Fund, an internationally recognized sponsor of digital asset treasury companies, including Metaplanet Inc., the world’s fifth-largest holder of bitcoin. The company expects to raise between $12 million and $20 million in gross proceeds from the offering, consisting of common stock and warrants to purchase common stock. Benzinga reports.
2) IPDN: Professional Diversity
Total gain: +65.03%
The stock appeared to be moving on no notable news.
3) SSKN: Strata Skin Sciences
Total gain: +53.82%
The company highlighted a recent peer-reviewed, randomized controlled study evaluating its 308nm Excimer laser combined with an oral Janus kinase (JAK) inhibitor. The study demonstrated superior efficacy, unprecedented response rates, and a strong safety profile compared with monotherapy or conventional treatments. Conducted with 251 patients and published in the International Journal of Dermatology, the study titled “308nm Excimer Laser Combined with JAK Inhibitors for Adult Localized Non-Segmental Vitiligo: A Multicenter Randomized Controlled Trial” underscores the continued interest in the company’s established technology. It also shows that combination therapy achieved faster, more effective, and longer-lasting repigmentation than monotherapy. Benzinga reports.
*Estimate and Actual numbers represent Earnings Per Share in US Dollars
SFIX: Stitch Fix
Q4 2025
After Market Close
Estimate: -0.110
Actual: N/A
UEC: Uranium Energy
Q4 2025
Before Market Open
Estimate: -0.040
Actual: N/A
KBH: KB Home
Q3 2025
After Market Close
Estimate: 1.500
Actual: N/A
Time (ET) | Report | Period
10:00 AM - New home sales - August
4:10 PM - San Francisco Fed President Mary Daly speech
“Every trader has strengths and weakness. Some are good holders of winners, but may hold their losers a little too long. Others may cut their winners a little short, but are quick to take their losses. As long as you stick to your own style, you get the good and bad in your own approach.”
- Michael Marcus
Sourced in: 17 of the Best Trading Quotes of All-Time by Trading Heroes.
TradeZero America, Inc., a United States broker dealer, registered with the Securities and Exchange Commission (SEC) and member of the Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC); TradeZero, Inc., a Bahamian broker dealer, registered with the Securities Commission of the Bahamas; and TradeZero Canada Securities ULC, a Canadian broker dealer, member firm of the Canadian Investment Regulatory Organization (CIRO) and member of the Canadian Investor Protection Fund (CIPF) (collectively the "TradeZero Broker Dealers”) are subsidiaries of TradeZero Holding Corp.
TradeZero Broker Dealers offer self-directed electronic securities trading to their customers. TradeZero Broker Dealers do not provide financial or trading advice and do not make investment recommendations to their customers. This communication does not constitute an offer to sell or a solicitation to buy any security or instrument which it may reference. There is a risk of loss in online trading of securities including equities and options. Trading on margin is for experienced investors only as the amount you may lose can be greater than your initial investment. Likewise, short selling as a securities trading strategy is extremely risky and can lead to potentially unlimited losses. Options trading is not suitable for all investors as it can involve risk that may expose investors to significant losses. Please read the Characteristics and Risks of Standardized Options, also known as the options disclosure (ODD) at OCC before deciding to engage in options trading.
If you have any specific questions about TradeZero's brokerage services, please reach out to the TradeZero Broker Dealer servicing your jurisdiction.